• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Nightingale's remote tests to be included in Supernormal's weight loss service

HEALTHAnalyst Comment19.08.2026, 09.12
Antti SiltanenAnalyst
Discuss

Summary

  • Nightingale Health has partnered with Supernormal to integrate its at-home blood test into Supernormal's medical weight loss programs in Finland.
  • The collaboration is expected to generate recurring sample demand due to Supernormal's over 10,000 members, although the immediate financial impact is estimated to be minor.
  • The partnership highlights the commercial demand for Nightingale's technology and serves as a reference for potential larger-scale international collaborations.
  • The scalability and profitability of Nightingale's business model depend on establishing numerous healthcare partnerships and increasing volumes over the long term.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 8/19/2026 at 7:00 am EEST.

Nightingale Health announced on Tuesday that it has partnered with Supernormal, a Finnish provider of medical weight loss services. With the agreement, Nightingale's at-home blood test (Remote Health Check) will be integrated into Supernormal's treatment programs, where customers' metabolic health is monitored, for example, during GLP-1 medication. While the news is a positive indication of commercial demand for the technology, we estimate that the financial impact of the agreement will remain minor for now.

According to the company, Supernormal has over 10,000 members, and the utilization of tests before and during treatment inherently creates recurring sample demand for Nightingale. The rapid adoption of GLP-1 drugs has created a need in healthcare to verify the broader health benefits of weight loss. In our view, Nightingale's cost-effective and comprehensive blood analysis is an excellent fit for this purpose. While the volumes generated by the Supernormal collaboration alone do not change Nightingale's overall financial picture, the collaboration serves as a good reference for similar international clinics, which may be significantly larger in scale. As we have emphasized before, the scalability of Nightingale's business model and the turnaround in profitability require the company to establish numerous healthcare partnerships and consistently increase their volumes over the long term.

Nightingale Health operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes platforms and services within blood analysis that are used for disease prevention purposes. In addition to the main business, service and related ancillary services are also offered. The business is operated globally with the largest presence in Europe.

Read more on company page

Key Estimate Figures11.06

202526e27e
Revenue4.75.910.2
growth-%7.7 %25.9 %71.7 %
EBIT (adj.)-19.4-17.8-13.9
EBIT-% (adj.)-413.7 %-301.2 %-137.3 %
EPS (adj.)-0.30-0.29-0.21
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

It inevitably makes you wonder if it might be time to replace the “finger-twister” (CEO/leader) as well? There’s plenty of positive buzz coming...
1 hour ago
by Turskanuotta
2
He already knew the company, so he knew exactly what he was getting into. A good sign.
1 hour ago
by Pertti
3
This is a reasonably positive sign, as Boston Heart Diagnostics is already a strategic partner of Nightingale, meaning someone is switching ...
4 hours ago
by NukkeNukuttaja
11
Boy, there are a lot of press releases coming out now… US Healthcare Business Executive Hugh Watson Appointed as Chief Commercial Officer for...
5 hours ago
by Tuuukka
13
Inderes – 19 Aug 26 Nightingalen etätestit osaksi Supernormalin painonhallintapalvelua - Inderes Yli 10 000 jäsenen Supernormal-yhteistyö vie...
7 hours ago
by Pertti
9
The home test apparently utilized by Supernormal was, from a consumer’s perspective, a quite functional and convenient service that I would ...
yesterday
by Yariskuski
18
Inderes Nightingale Healthin Remote Health Check osaksi Supernormalin lääkkeellistä... Nightingale Health Oyj | Lehdistötiedote | 18.08.2026...
yesterday
by Pertti
14